• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Eisai is licking chops at their Arena takeunder

Anonymous

Guest
I love how they created this "incentive" program to slow-play the sales reps. If I was Arena Pharma, I would NEVER sell to Eisai. Any one out there knows they are intentionally looking for a slow launch. Any one else told to go "SLOW AND STEADY" what kind of sales strategy is that?